NEW YORK, March 9, 2026, 11:11 EDT.
Biohaven Ltd stock swung sharply Monday, starting out at $11.38, then spiking up to $12.70, only to fade back to $9.91 by 10:55 a.m. EDT. The action came as rare-disease biotech names drew fresh interest following a shift at the U.S. Food and Drug Administration. Trading volume crossed 3.1 million shares early.
This move comes after Biohaven, among other drug developers, faced a rare-disease regulatory setback last November. Prasad’s division was under fire for its approach to rare-disease drug reviews. Shares of uniQure surged 57% in after-hours trading following Friday’s news of his departure. Stifel’s Paul Matteis described it as “a big win for biotech,” according to comments picked up by Investing.com on Monday. Reuters
Biohaven saw its stock dive over 40% in November after the FDA handed down a complete response letter—that’s a formal rejection—for Vyglxia, also known as troriluzole. The drug targets spinocerebellar ataxia, a rare neurological condition that disrupts movement and balance. According to the agency, Biohaven relied on real-world evidence—patient data collected outside the traditional randomized trial setup—and external controls, both of which the FDA flagged for possible bias and study design shortcomings.
Biohaven isn’t letting the issue go. The company’s senior medical director, Melissa Beiner, told PharmaVoice last month that rare-disease applicants deserve an “equal and fair review.” She pointed to inconsistent decisions that, in her words, have left patients stuck in limbo. PharmaVoice
Biohaven on March 2 flagged three main spending targets: protein degraders—these are drugs aimed at clearing harmful proteins from the body—along with opakalim for focal epilepsy, and taldefgrobep in obesity. CEO Vlad Coric pointed to “critical milestones are on the horizon this year.” SEC
The company posted a net loss of $738.8 million for 2025, trimming last year’s $846.4 million deficit. By December, it held roughly $322 million combined in cash, equivalents, marketable securities, and restricted cash. Afterward, it raised $178.9 million from a 17.2 million-share sale, but also had to make a $42.7 million payment related to its Knopp Biosciences liability.
Analyst backing remains in place. As of March 5, Reuters stock data listed 18 analysts tracking Biohaven, with a consensus rating of Outperform. Still, RBC’s Leonid Timashev warned after the November rejection that the company had a “difficult road ahead” unless it could deliver more trial data. Reuters
Some investors are taking the view that a change at the FDA might finally give rare-disease drug developers some breathing room. Biohaven, though, still faces a gantlet: it needs to deliver on late-2026 epilepsy and obesity results, advance its degrader pipeline, and deal with a balance sheet that’s already tapped new equity—so dilution risk isn’t going away.
